Louise Chen
Stock Analyst at Scotiabank
(3.54)
# 790
Out of 5,182 analysts
293
Total ratings
47.74%
Success rate
22.86%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Sector Outperform | $35 → $40 | $31.62 | +26.50% | 5 | Jan 29, 2026 | |
| JNJ Johnson & Johnson | Maintains: Sector Outperform | $230 → $265 | $227.79 | +16.34% | 41 | Jan 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $58.26 | +2.99% | 2 | Jan 9, 2026 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $110.03 | +9.06% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $731.77 | +5.22% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $21.07 | +279.69% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $4.22 | +113.27% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $30.99 | -54.82% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.85 | +548.65% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $23.69 | +132.17% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $55 | $70.26 | -21.72% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $3.95 | +279.75% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $125.96 | -60.30% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.97 | +151.26% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $36.34 | -53.22% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $18.16 | +175.33% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $7.94 | +277.83% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $22.14 | +148.42% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.67 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $41.17 | +288.63% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $58.73 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $197.69 | +21.40% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $26.48 | +69.94% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.90 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.77 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $874.00 | +1.26% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.27 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.99 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.22 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.49 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.17 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.96 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.08 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.99 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.43 | +1,795.04% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.40 | +108.33% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.59 | +267.92% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $23.32 | +114.41% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.10 | +138.10% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.64 | +1,306.47% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.24 | +700,207,368.88% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $229.56 | +12.39% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.21 | +4,032.23% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.21 | +1,552.89% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.26 | +755.51% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Jan 29, 2026
Maintains: Sector Outperform
Price Target: $35 → $40
Current: $31.62
Upside: +26.50%
Johnson & Johnson
Jan 22, 2026
Maintains: Sector Outperform
Price Target: $230 → $265
Current: $227.79
Upside: +16.34%
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $58.26
Upside: +2.99%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $110.03
Upside: +9.06%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $731.77
Upside: +5.22%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $21.07
Upside: +279.69%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $4.22
Upside: +113.27%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $30.99
Upside: -54.82%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.85
Upside: +548.65%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $23.69
Upside: +132.17%
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $70.26
Upside: -21.72%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.95
Upside: +279.75%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $125.96
Upside: -60.30%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.97
Upside: +151.26%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $36.34
Upside: -53.22%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $18.16
Upside: +175.33%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $7.94
Upside: +277.83%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $22.14
Upside: +148.42%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.67
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $41.17
Upside: +288.63%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $58.73
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $197.69
Upside: +21.40%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.48
Upside: +69.94%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.90
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.77
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $874.00
Upside: +1.26%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.99
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.22
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.49
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.17
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.96
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.08
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.99
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.43
Upside: +1,795.04%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.40
Upside: +108.33%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.59
Upside: +267.92%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $23.32
Upside: +114.41%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.10
Upside: +138.10%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.64
Upside: +1,306.47%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.24
Upside: +700,207,368.88%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $229.56
Upside: +12.39%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.21
Upside: +4,032.23%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.21
Upside: +1,552.89%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $5.26
Upside: +755.51%